Gewinn- und Verlustrechnung von Medpace Holdings, Inc.

Medpace (MEDP) reported earnings 30 days ago. What's next for the stock?

Abacus FCF Advisors LLC acquired a new stake in shares of Medpace Holdings, Inc. (NASDAQ: MEDP) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 12,529 shares of the company's stock, valued at approximately $6,635,000. Several other institutional investors

Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.

Medpace Holdings, Inc. (NASDAQ: MEDP - Get Free Report) CEO August Troendle sold 11,366 shares of the business's stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $601.53, for a total value of $6,836,989.98. Following the completion of the sale, the chief executive officer owned 604,436 shares in

Investors interested in stocks from the Medical Services sector have probably already heard of Concentra Group (CON) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

NEW YORK, Aug. 10, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Medpace Holdings, Inc. (NASDAQ: MEDP)  breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, Medpace Holdings misrepresented or failed to disclose material information concerning the Company's backlog cancellation rates, business conditions, and ability to maintain its projected 1.15 book-to-bill ratio.

Medpace Holdings, Inc. (MEDP) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MEDP's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.

Medpace pairs double-digit growth, record awards and a strong balance sheet with a rich valuation, raising the question of whether the premium already prices in its outlook.

Medpace Holdings, Inc.  MEDP regained commercial momentum in the second quarter of 2026 as record awards and a higher book-to-bill ratio reversed the weaker first-quarter trend.